We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New TB Test Will Dramatically Cut Diagnosis Time

By LabMedica International staff writers
Posted on 26 Mar 2009
An onsite method was developed to quickly diagnose tuberculosis (TB) and expose the deadly drug-resistant strains that can mingle undetected with treatable TB strains.

The gene for green fluorescence protein (GFP) was implanted in the genome of bacteriophages, tiny viruses that attack bacteria. More...
Bacteriophages inject their DNA into bacterial cells in order to multiply. The GFP gene accompanies the DNA of the phage into the Mycobacterium tuberculosis cell, the bacterium that causes TB, causing the cell to glow. A clinician can detect the glow with equipment available at many clinics.

The test was also used to distinguish treatable TB strains from those that are drug resistant (DR-TB) and extensively drug resistant (XDR-TB), which normally takes months. The scientists treated M. tuberculosis with antibiotics at the same time the bacteriophages were introduced; the TB strains that were sensitive to antibiotics died, but the drug-resistant cells survived and continued to glow.

Scientists from the Albert Einstein College of Medicine (Bronx, NY, USA) and The University of Pittsburgh (Pittsburg, PA, USA) developed the rapid diagnostic method for TB. "The development of these reporter flurophages allows us to bypass the existing method of diagnosing TB, which requires cultivating slow-growing bacteria in a biosafety level 3 environment, a time-consuming and costly process," said William R. Jacobs, Jr., Ph.D., one of the team that developed the test. "By infecting live M. tuberculosis cells with a flurophage, a quick and highly sensitive visual reading can be done. We are optimistic that we can move the diagnostic process from several weeks to several days or even hours, which could have a significant impact on treatment."

The study appeared in the March 19, 2009 edition of PLoS ONE.

Related Links:

Albert Einstein College of Medicine
The University of Pittsburgh


Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.